ArticleOncology letters2016
Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.BMC gastroenterology · 2020Pooled it
- Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Thymosin α1 Combined with PD-1/PD-L1 Inhibitor Plus Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer : A Retrospective Analysis.Cancer management and research · 2025Article
- Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.Molecules (Basel, Switzerland) · 2023Review
- A Reappraisal of Thymosin Alpha1 in Cancer Therapy.Frontiers in oncology · 2019Review
- Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical efficacy of thymosin α1 (Tα1) therapy in patients with hepatocellular carcinoma (HCC) subsequent to radical hepatectomy is unclear. In the present study, the impact of Tα1 therapy on outcomes in HCC patients after radical hepatectomy was retrospectively evaluated. Medical records were retrospectively reviewed for 146 patients with hepatitis B virus (HBV)-associated HCC who were treated by radical hepatectomy and subsequently with Tα1 therapy, as well as for 412 control patients with HBV-associated HCC treated by radical hepatectomy. Propensity score matching was used to minimize confounding variables due to baseline differences. Liver function, recurrence-free survival and overall survival rates were compared between the two groups. Serum markers of liver function were significantly improved in the Tα1 group compared with the control group. The 1-, 2- and 3-year overall survival rates were 87.2, 82.0 and 68.4% in the Tα1 group and 78.2, 64.2 and 49.7% in the control group (P=0.011). The 1-, 2- and 3-year recurrence-free survival rates were 79.7, 70.8 and 67.3% in the Tα1 group and 69.9, 61.5 and 51.6% in the control group (P=0.019). The results suggested that post-hepatectomy Tα1 therapy improves liver function and significantly prolong recurrence-free and overall survival in patients with HBV-associated HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.